Huai-Xiang Hao

3.4k total citations · 1 hit paper
12 papers, 1.4k citations indexed

About

Huai-Xiang Hao is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Huai-Xiang Hao has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Huai-Xiang Hao's work include Cancer Mechanisms and Therapy (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer-related gene regulation (3 papers). Huai-Xiang Hao is often cited by papers focused on Cancer Mechanisms and Therapy (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer-related gene regulation (3 papers). Huai-Xiang Hao collaborates with scholars based in United States, Switzerland and China. Huai-Xiang Hao's co-authors include Feng Cong, Xiaomo Jiang, Olga Charlat, Jeffery A. Porter, Fabrizio C. Serluca, Craig Mickanin, Yue Zhang, Heinz Ruffner, Marc W. Kirschner and Raffaella Zamponi and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Cancer Research.

In The Last Decade

Huai-Xiang Hao

12 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner

2012 709 citations Huai-Xiang Hao, Yang Xie et al. Nature profile →

Peers

Countries citing papers authored by Huai-Xiang Hao

Since Specialization

Citations

This map shows the geographic impact of Huai-Xiang Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huai-Xiang Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huai-Xiang Hao more than expected).

Fields of papers citing papers by Huai-Xiang Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huai-Xiang Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huai-Xiang Hao. The network helps show where Huai-Xiang Hao may publish in the future.

Co-authorship network of co-authors of Huai-Xiang Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Huai-Xiang Hao. A scholar is included among the top collaborators of Huai-Xiang Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huai-Xiang Hao. Huai-Xiang Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition 2022 ·Cell Reports ·Jinyang Cai, Sheeba Jacob, Richard Kurupi, (unknown), (unknown), Patricia Greninger, Regina K. Egan, Giovanna T. Stein, Ellen Murchie, Joseph McClanaghan, Yuta Adachi, (unknown), Mikhail G. Dozmorov, John Glod, Sosipatros A. Boikos, Hiromichi Ebi, Huai-Xiang Hao, Giordano Caponigro, Cyril H. Benes, Anthony C. Faber	10
2	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 2020 ·Investigational New Drugs ·Jean‐Pierre Delord, Guillem Argilés, Jérôme Fayette, Lori J. Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesı́a, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel, Sylvia Zhao, (unknown), Huai-Xiang Hao, Ralph Tiedt, (unknown), Andrea P. Myers, Lillian L. Siu	17
3	FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma 2020 ·Experimental & Molecular Medicine ·Hung Huynh, (unknown), Thi Bich Uyen Le, (unknown), Huai-Xiang Hao, Alan Huang, Youzhen Wang, Diana Graus Porta	19
4	Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma 2020 ·Oncotarget ·Wen Luo, Changxin Xu, (unknown), (unknown), Jeremy Rosenblum, Janet Ayello, Stephen L. Lessnick, Huai-Xiang Hao, Mitchell S. Cairo	9
5	Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation 2019 ·Clinical Cancer Research ·Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T. DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang, Pascal Furet, William R. Sellers, Francesco Hofmann, Joseph Schoepfer, Ralph Tiedt	105
6	Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors 2019 ·Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, (unknown), (unknown), (unknown), Éric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai-Xiang Hao	1
7	Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody 2018 ·Journal of Translational Medicine ·(unknown), Phillip R. Musich, Ben Staal, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Wei‐Zhong Wu, Angela Tam, Alan Huang, Huai-Xiang Hao, George F. Vande Woude, Qian Xie	23
8	Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer 2016 ·Cancers ·Huai-Xiang Hao, Xiaomo Jiang, Feng Cong	134
9	Abstract 4630: The pan-PIM inhibitor PIM447 enhances the antitumor activity of lenalidomide in multiple myeloma cells via synergistic inhibition of c-MYC 2016 ·Cancer Research ·Huai-Xiang Hao, (unknown), Gary Vanasse, Giordano Caponigro	2
10	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus 2015 ·Molecular Cancer Therapeutics ·Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David T. Yang, David A. Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, Alan Huang	60
11	Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma 2013 ·Proceedings of the National Academy of Sciences ·Xiaomo Jiang, Huai-Xiang Hao, Joseph D. Growney, Steve Woolfenden, (unknown), Nicholas Ng, Bo Lü, Mindy H. Hsieh, (unknown), Ronald A. Meyer, Timothy R. Smith, (unknown), Olga Charlat, Yang Xie, Jeffery A. Porter, Shifeng Pan, Jun Liu, Margaret E. McLaughlin, Feng Cong	325
12	ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner breakdown → 2012 ·Nature ·Huai-Xiang Hao, Yang Xie, Yue Zhang, Olga Charlat, (unknown), (unknown), Hong Lei, Craig Mickanin, Dong Liu, Heinz Ruffner, Xiaohong Mao, Qicheng Ma, Raffaella Zamponi, Tewis Bouwmeester, Peter M. Finan, Marc W. Kirschner, Jeffery A. Porter, Fabrizio C. Serluca, Feng Cong	709

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact